-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the continuous increase of COVID-19 cases in the United States and around the world, there are still very few treatment options for SARS-CoV-2 patients
.
But a new study from the University of Georgia offers hope for a viable treatment.
The disease has claimed more than 4 million lives worldwide
.
The study, published in Scientific Reports under the journal Nature , found that Probenecid (Probenecid) has a wide range of antiviral properties, making it an effective fight against SARS-CoV-2 infection and other common and deadly respiratory viruses, such as The drug of choice for RSV and influenza
.
Probenecid is a drug approved by the FDA mainly for the treatment of gout and has been widely used in the United States
.
The drug has been on the market for more than 40 years with very few side effects
The lead author of the study, Ralph Tripp, a distinguished scholar in the Vaccine and Therapeutic Research GRA at the University of Georgia School of Veterinary Medicine, said: "There is really nothing that can safely fight these viruses
.
This antiviral drug is good for us.
Block virus replication
The working principle of viruses is to use the body's own cells to replicate and produce more viruses
.
Probenecid blocks the replication process and prevents the virus from infecting individual cells
Tripp demonstrated the preventive effect of the drug before exposure to the virus, as well as its therapeutic effect on SARS-CoV-2 and influenza after exposure in animal models
.
The drug has also been proven to be effective against RSV in vitro, and research in vivo is ongoing
Although the drug is mainly used in people who are positive for the virus, the results of prevention studies mean that people who are known to have been exposed to the virus may also take the drug to prevent disease
.
COVID-19 Treatment Options Ltd
Remdesivir and monoclonal antibodies currently used to treat severe COVID-19 patients can only be injected intravenously
.
By the time COVID-19 patients need them, it is often too late
Tripp said: "These treatments have some effects on SARS-CoV-2, but they are very expensive and difficult to obtain
.
In reality, due to cost reasons, limitations of intravenous injections and lack of access, there are only a few options available.
On the other hand, Probenecid is widely used
.
Primary care doctors can prescribe medicines to patients, or they can pick them up from local pharmacies
It is common to reuse a medicine that has been approved to treat a problem
.
For example, Remdesivir was originally used to fight the Ebola virus, but when it showed some promise in the fight against the coronavirus, it was used to fight COVID-19
In addition to prevention before the disease starts, probenecid may also increase the efficacy of other treatments
.
Probenecid has been used to increase the effectiveness of some antibiotics, so this drug may also work with other COVID-19 treatments
.
Now, researchers are studying what dosage of probenecid can have the greatest effect on the fight against human viruses
.
The pharmaceutical company TrippBio will begin clinical trials of the drug within this year
.
Tripp said: "SARS-CoV-2, respiratory confluence virus and influenza have a huge impact on the health system around the world
.
Probenesulfide has an effective antiviral effect on these viruses, and it is very safe
.
"
Probenecid has been approved by the FDA and has effective antiviral properties against SARS-CoV-2
.
References: Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro by Jackelyn Murray, Robert J.
Hogan, David E.
Martin, Kathy Blahunka, Fred D.
Sancilio, Rajiv Balyan, Mark Lovern, Richard Still and Ralph A.
Tripp, 10 September 2021, Scientific Reports .
DOI: 10.
1038/s41598-021-97658-w
